Literature DB >> 9757575

Evaluation of the macrocyclic antibiotic avoparcin as a new chiral selector for HPLC.

K H Ekborg-Ott1, J P Kullman, X Wang, K Gahm, L He, D W Armstrong.   

Abstract

Avoparcin is a macrocyclic glycopeptide antibiotic structurally related to vancomycin, teicoplanin, and ristocetin A. When attached to 5-microns spherical silica gel, the avoparcin proved to be an effective chiral stationary phase (CSP) that could be used in the reversed-phase, normal-phase, and polar-organic modes. The avoparcin CSP was complimentary to the other macrocyclic glycopeptide CSPs in that it could resolve some racemates that the others could not, and vice versa. Some important compounds resolved on the avoparcin CSP include verapamil, thyroxine, mephenytoin, and 2-imidazolidone-4-carboxylic acid. The use of this CSP and the optimization of separations on it are discussed. Avoparcin appears to be a useful addition to this family of CSPs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9757575     DOI: 10.1002/(SICI)1520-636X(1998)10:7<627::AID-CHIR10>3.0.CO;2-1

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  3 in total

1.  Evaluation of dalbavancin as chiral selector for HPLC and comparison with teicoplanin-based chiral stationary phases.

Authors:  Xiaotong Zhang; Ye Bao; Ke Huang; Kimber L Barnett-Rundlett; Daniel W Armstrong
Journal:  Chirality       Date:  2010-05-15       Impact factor: 2.437

2.  Enantiomeric Separation of New Chiral Azole Compounds.

Authors:  Marziyeh E Kenari; Joshua I Putman; Ravi P Singh; Brandon B Fulton; Huy Phan; Reem K Haimour; Key Tse; Alain Berthod; Carl J Lovely; Daniel W Armstrong
Journal:  Molecules       Date:  2021-01-04       Impact factor: 4.411

3.  Mass spectrometry detection of basic drugs in fast chiral analyses with vancomycin stationary phases.

Authors:  Hongyue Guo; M Farooq Wahab; Alain Berthod; Daniel W Armstrong
Journal:  J Pharm Anal       Date:  2018-08-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.